Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

731.34 -14.35 (-1.92%)
Streaming Delayed Price Updated: 12:30 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 998,457
Open 752.64
Bid (Size) 731.24 (2)
Ask (Size) 731.79 (4)
Prev. Close 745.69
Today's Range 728.78 - 752.64
52wk Range 370.68 - 800.78
Shares Outstanding N/A
Dividend Yield 0.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Lilly recently announced news that could solve a big problem. 
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace

Performance

YTD
+23.50%
+23.50%
1 Month
-5.41%
-5.41%
3 Month
+16.14%
+16.14%
6 Month
+23.45%
+23.45%
1 Year
+90.78%
+90.78%

More News

Read More
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
REITs Q1 Earnings Begin On Solid Note
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Via InvestorPlace
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Via Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
Via InvestorPlace
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
6 Stocks Positioned to Soar as Investors Focus on MASH
Via TheNewswire.com
Capturing Consumer Spending on Health Care with XLV
Via News Direct
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
SPDR ETF Report For Friday, April 19
Via Talk Markets
Topics ETFs
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
Via InvestorPlace
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Via InvestorPlace
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.